Drug Profile
OVI 237
Alternative Names: 1843U89; BW 1843U89; GS 7904L; GW 1843U89; Liposomal OSI 7904; OSI-7904L; OVI-237Latest Information Update: 16 Jun 2011
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Developer OncoVista
- Class Antimalarials; Antineoplastics
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Biliary cancer; Cancer; Malaria
Most Recent Events
- 31 Mar 2011 Discontinued - Phase-II for Cancer in USA (unspecified route)
- 06 Dec 2007 OSI 7904L licensed to OncoVista worldwide
- 31 May 2004 Phase-II clinical trials in Biliary cancer in Europe (IV-infusion)